CD274 and non-small cell lung carcinoma: Several randomized clinical trials (RCT) have demonstrated an OS benefit for the addition of anti-PD-1/PD-L1 antibodies to platinum-based chemotherapy, providing new frontline treatment strategies for metastatic NSCLC.